Latest Glycosides Stories
ERLANGER, Ky., July 2 /PRNewswire/ -- WILD Flavors continues its commitment to health, wellness, and natural products by promoting the broader use of Stevia through WILD's entire line of Sunwin Stevia(TM) products -- all FDA GRAS affirmed (FDA Letters of No Objection #GRN000303 & #GRN000304).
IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a world leader in phytochemical reference standards and contract testing services, announced that Frank Jaksch, president and co-founder, will be presenting on stevia testing and quality control at the European Stevia Association (EUSTAS) Fourth International Stevia Symposium on Tuesday, June 29 at 2 p.m.
COLUMBIA, Md., June 14 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDoxÂ® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology (ASTRO) Annual Meeting.
COLUMBIA, Md., June 8 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDoxÂ® in Recurrent Chest Wall (RCW) Breast Cancer was presented at a poster session on June 7, 2010 at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting.
Encouraging trend observed in overall survival QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
CHICAGO, May 25 /PRNewswire/ -- Stevia, the naturally zero-calorie sweetener, is gaining in popularity with consumers and food manufacturers alike.
QUEBEC CITY, May 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen.
SEATTLE, May 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S.
Bittercress (Barbarea vulgaris), also commonly known as Herb Barbara, Rocketcress, Yellow Rocketcress, Winter Rocket, and Wound Rocket, is a European biennial herb. This plant displays a rosette of shiny, dark green leaves at the base and additional pinnately divided leaves on the stem. In the spring, yellow flowers originate in tightly packed terminal groups just above the foliage. Bittercress grows wildly as a weed in many parts of North America. The flowers can be in bloom May...
- To swell, as grain or wood with water.